These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

797 related items for PubMed ID: 9475762

  • 1. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J.
    N Engl J Med; 1998 Feb 26; 338(9):557-63. PubMed ID: 9475762
    [Abstract] [Full Text] [Related]

  • 2. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS.
    N Engl J Med; 1992 Oct 22; 327(17):1185-91. PubMed ID: 1383816
    [Abstract] [Full Text] [Related]

  • 3. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J, Proscar Long-Term Efficacy and Safety Study Group.
    J Urol; 2004 Mar 22; 171(3):1194-8. PubMed ID: 14767299
    [Abstract] [Full Text] [Related]

  • 4. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group.
    N Engl J Med; 2003 Dec 18; 349(25):2387-98. PubMed ID: 14681504
    [Abstract] [Full Text] [Related]

  • 5. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan 18; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 6. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ.
    N Engl J Med; 1996 Aug 22; 335(8):533-9. PubMed ID: 8684407
    [Abstract] [Full Text] [Related]

  • 7. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ.
    Urology; 1998 May 22; 51(5):677-86. PubMed ID: 9610579
    [Abstract] [Full Text] [Related]

  • 8. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.
    Urology; 2011 Sep 22; 78(3):641-6. PubMed ID: 21764428
    [Abstract] [Full Text] [Related]

  • 9. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G.
    J Urol; 2006 Sep 22; 176(3):1051-6. PubMed ID: 16890690
    [Abstract] [Full Text] [Related]

  • 10. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA.
    East Afr Med J; 1998 May 22; 75(5):260-3. PubMed ID: 9746993
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct 22; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 12. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E.
    Arch Intern Med; 1994 Jan 10; 154(1):83-8. PubMed ID: 7505563
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
    Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM.
    CMAJ; 1996 Nov 01; 155(9):1251-9. PubMed ID: 8911291
    [Abstract] [Full Text] [Related]

  • 14. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
    Fenter TC, Davis EA, Shah MB, Lin PJ.
    Am J Manag Care; 2008 May 01; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
    [Abstract] [Full Text] [Related]

  • 15. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B, McConnell J.
    Wien Med Wochenschr; 1996 May 01; 146(8):165-8. PubMed ID: 8767401
    [Abstract] [Full Text] [Related]

  • 16. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG.
    BJU Int; 2006 Apr 01; 97(4):734-41. PubMed ID: 16536764
    [Abstract] [Full Text] [Related]

  • 17. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH, Meehan A, Lee M, Penson DF, Wessells H.
    J Urol; 2005 Mar 01; 173(3):903-7. PubMed ID: 15711315
    [Abstract] [Full Text] [Related]

  • 18. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.
    Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG.
    N Engl J Med; 1995 Jan 12; 332(2):75-9. PubMed ID: 7527493
    [Abstract] [Full Text] [Related]

  • 19. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
    Andersen JT, Wolf H, Ekman P, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K.
    Ugeskr Laeger; 1996 Sep 02; 158(36):5030-5. PubMed ID: 8928243
    [Abstract] [Full Text] [Related]

  • 20. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996 Sep 02; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.